



March 1, 2018

Pfizer Japan Inc.
Sumitomo Dainippon Pharma Co., Ltd.

Pfizer and Sumitomo Dainippon Pharma Commence the Co-Promotion of Serotonin-Norepinephrine Reuptake Inhibitor EFFEXOR® SR Capsules

Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo, President: Akihisa Harada, “Pfizer”) and Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka City, Osaka, President: Masayo Tada, “Sumitomo Dainippon Pharma”) announced today that the two companies will commence the co-promotion in Japan from April 1 of serotonin-noradrenaline reuptake inhibitor (SNRI) EFFEXOR® SR Capsules (generic name: Venlafaxine Hydrochloride), which was created by Pfizer and for which Pfizer has obtained manufacturing and marketing approval. Under the terms of the agreement signed by the two companies, Pfizer and Sumitomo Dainippon Pharma will jointly provide medical information on EFFEXOR® SR Capsules and Pfizer will remain responsible for its manufacturing and marketing.

Indicated for depression and depressed state, EFFEXOR® SR Capsules was launched by Pfizer in 2015 after manufacturing and marketing approval was obtained. It is believed that the drug is one of first-line agents in treating depression due to its ability to achieve remission by relieving anxiety symptoms and increasing motivation.

With the commencement of co-promotion, Pfizer and Sumitomo Dainippon Pharma will further enhance the provision of information on the drug, thereby promoting the appropriate use of EFFEXOR® SR Capsules in the treatment of depression.

The outline of EFFEXOR® SR Capsules

Product name	EFFEXOR®SR Capsules 37.5mg · 75mg
Generic name	Venlafaxine Hydrochloride (JAN)
Manufacturer/distributor	Pfizer Japan Inc.
Indications	Depression/ Depressed state
Dosage and administration	In general, for adults, start with 37.5 mg of venlafaxine at a time, once a day. After a week, take 75 mg at a time after meal, once a day. The dosage may be adjusted up to 225 mg per day according to the age or symptoms. The dosage may be increased by 75 mg at a day, with an interval of at least one week.

For further information, please refer to the label of EFFEXOR® SR Capsules

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407(Osaka)

+81-3-5159-3300 (Tokyo)